result
result
Active/Enrolling Clinical Trials
March 2023
Active/Enrolling Clinical Trials
March 2023
The Underwood Center reviews this list of active/enrolling clinical trials before publication. However, the status of the studies may change. Please contact the study coordinator to inquire about enrollment for your patient.
Disease/Condition
Alcoholic Hepatitis
PI
Victor, David
Particulars of Eligible Patient Population
Severe Alcoholic Hepatitis
Intervention
DUR-928 vs placebo
Contact
Marcos De Olivera,
mdeoliveira@houstonmethodist.org
Disease/Condition
Crohn's Disease
PI
Abraham, Bincy
Particulars of Eligible Patient Population
CD patients receiving ustekinumab induction treatment
Intervention
BI 706321 vs Placebo
Contact
Melissa Whipple,
mbwhipple@houstonmethodist.org
Disease/Condition
Crohn's Disease
PI
Abraham, Bincy
Particulars of Eligible Patient Population
Moderately to Severely Active Crohn's Disease
Intervention
Ozanimod vs placebo
Contact
Melissa Whipple,
mbwhipple@houstonmethodist.org
Disease/Condition
Crohn's Disease
PI
Abraham, Bincy
Particulars of Eligible Patient Population
Moderately to Severely Active Crohn's Disease
Intervention
Ozanimod
Contact
Melissa Whipple,
mbwhipple@houstonmethodist.org
Disease/Condition
Gastroparesis
PI
Dacha, Sunil
Particulars of Eligible Patient Population
Gastroparesis and non-gastroparesis patients scheduled for upper endoscopy
Intervention
EndoFLIP device
Contact
Melissa Whipple,
mbwhipple@houstonmethodist.org
Disease/Condition
GERD
PI
Kim, Min
Particulars of Eligible Patient Population
Gastroesophageal Reflux Disease
Intervention
LINX Reflux Management System
Contact
Lindsay Barter
lbarter@houstonmethodist.org
Disease/Condition
HCC
PI
Victor, David
Particulars of Eligible Patient Population
Cirrhosis & early HCC
Intervention
N/A - Biomarker study
Contact
Ahmed Elsaiey,
aelsaiey@houstonmethodist.org
Disease/Condition
IBD
PI
Abraham, Bincy
Particulars of Eligible Patient Population
Pregnant women with IBD and their infants through 18 years old that have been exposed to a biologic, small molecule, or immunomodulator at any time through delivery.
Intervention
N/A - Registry study with questionnaires and blood samples
Contact
Melissa Whipple,
mbwhipple@houstonmethodist.org
Disease/Condition
IBD
PI
Abraham, Bincy
Particulars of Eligible Patient Population
IBD patients with UC or CD taking a new eligible immunosuppressant, biologic, or small molecue medication listed in protocol
Intervention
N/A - Registry study with questionnaires and blood samples
Contact
Melissa Whipple,
mbwhipple@houstonmethodist.org
Disease/Condition
IBD-Arthropathy
PI
Abraham, Bincy
Particulars of Eligible Patient Population
IBD Arthropathy with active joint symptoms who would be treated with celecoxib as SOC
Intervention
Curcumin vs Celecoxib
Contact
Melissa Whipple,
mbwhipple@houstonmethodist.org
Disease/Condition
NASH
PI
Victor, David
Particulars of Eligible Patient Population
NASH with compensated Cirrhosis (F4) due to NASH
Intervention
Semaglutide and a fixed-dose combination Cilofexor/Firsocostat
Contact
Nikki Hinton,
nhinton@houstonmethodist.org
Disease/Condition
NASH
PI
Victor, David
Particulars of Eligible Patient Population
Compensated cirrhosis due to NASH (F4)
Intervention
BMS-986263 vs placebo
Contact
Miguel Valdivia y Alvarado,
mvaldiviayalvarado@houstonmethodist.org
Disease/Condition
NASH
PI
Victor, David
Particulars of Eligible Patient Population
NASH (NAS > 4) with liver fibrosis (F2-F3)
Intervention
Semaglutide vs placebo
Contact
Nikki Hinton,
nhinton@houstonmethodist.org
Disease/Condition
NASH
PI
Victor, David
Particulars of Eligible Patient Population
NASH with liver fibrosis F2-F3)
Intervention
Lanifibranor vs placebo
Contact
Miguel Valdivia y Alvarado,
mvaldiviayalvarado@houstonmethodist.org
Disease/Condition
PBC
PI
Victor, David
Particulars of Eligible Patient Population
Primary Biliary Sholangitis
Intervention
Bezafibrate in combination with Obeticholic acid
Contact
Miguel Valdivia y Alvarado,
mvaldiviayalvarado@houstonmethodist.org
Disease/Condition
PSC
PI
Victor, David
Particulars of Eligible Patient Population
Primary Sclerosing Cholantitis (PSC) with Adult tchRO Score > 4
Intervention
Volixibat vs Placebo
Contact
Miguel Valdivia y Alvarado,
mvaldiviayalvarado@houstonmethodist.org